Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.06 USD | +3.62% |
|
+0.56% | -19.69% |
Jun. 14 | Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup | DJ |
Jun. 14 | EU regulator mandates label updates on CAR-T cancer therapies | RE |
Evolution of the average Target Price on Gilead Sciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Gilead Sciences, Inc.
UBS | |
Deutsche Bank Securities | |
Maxim | |
Redburn Atlantic | |
Barclays | |
TD Cowen | |
Jefferies & Co. | |
RBC Capital Markets | |
Morgan Stanley | |
HSBC | |
Argus | |
Cantor Fitzgerald | |
BMO Capital | |
Leerink Partners | |
Goldman Sachs | |
Wells Fargo Securities | |
Mizuho Securities | |
Truist Securities | |
Oppenheimer | |
Piper Sandler | |
BofA Securities | |
SVB Securities LLC | |
Cowen | |
JPMorgan Chase | |
SVB Leerink | |
Credit Suisse | |
Bernstein | |
Redburn | |
DZ BANK | Elmar Kraus |
EPS Revisions
- Stock Market
- Equities
- GILD Stock
- Consensus Gilead Sciences, Inc.